[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349677-105":59,"doc-detail-349677-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","a-novel-mpt-driven-necrosis-related-lncrna-signature-for-prognostic-prediction-in-hepatocellular-carcinoma-validation-using-organoids","A Novel MPT-Driven Necrosis-Related lncRNA Signature for Prognostic Prediction in Hepatocellular Carcinoma - Validation Using Organoids","","Mitochondrial permeability transition (MPT)-driven necrosis is a programmed cell death modality that shapes tumor progression, therapy response, and prognosis, yet MPT-driven necrosis-related long non-coding RNAs (MPTDNRlncRNAs) in hepatocellular carcinoma (HCC) remain insufficiently studied. This work constructs an MPTDNRlncRNA signature for survival prediction and patient stratification using TCGA RNA sequencing and clinical data, integrating MPT-linked necrosis gene sets from GSEA, and applying LASSO-Cox modeling. Immune infiltration differences and pathway variations between risk groups are evaluated, and the signature’s prognostic value is assessed with survival and time-dependent ROC analyses, including hub function validation of LINC02313 in organoid models.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-novel-mpt-driven-necrosis-related-lncrna-signature-for-prognostic-prediction-in-hepatocellular-carcinoma-validation-using-organoids/349677/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-novel-mpt-driven-necrosis-related-lncrna-signature-for-prognostic-prediction-in-hepatocellular-carcinoma-validation-using-organoids/349677.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s main goal for hepatocellular carcinoma patients?","Question",{"text":112,"@type":113},"To develop an MPT-driven necrosis-related lncRNA signature that predicts survival and classifies HCC patients into risk groups, with prognostic performance assessed statistically.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were candidate lncRNAs and the predictive signature constructed?",{"text":117,"@type":113},"RNA sequencing and clinical data were obtained from TCGA, MPT-driven necrosis-linked genes were taken from GSEA, and a seven-lncRNA signature was built using LASSO-Cox analysis on HCC tumor tissues.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence links the signature to immune features and HCC prognosis?",{"text":121,"@type":113},"Correlation analyses associate the lncRNA signature with immune cell infiltration and immune checkpoint targets, and survival-focused analyses demonstrate significant prognostic value between high- and low-risk groups.",{"name":123,"@type":110,"acceptedAnswer":124},"How was the role of LINC02313 validated experimentally?",{"text":125,"@type":113},"LINC02313 was identified as a hub lncRNA and its function was further validated using a liver cancer organoid model to support its role in promoting proliferation and metastasis.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},349677,1790212433,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Cancer Medicine  \n|  RESEARCH ARTICLE  OPEN ACCESS \u003Cbr>A Novel MPT-Driven Necrosis-Related lncRNA Signature for Prognostic Prediction in Hepatocellular Carcinoma:\u003Cbr>Validation Using Organoids\u003Cbr>Yang Liu1,2,3,4  | Liye Tao1,2,3,4 | Zefeng Shen1,2,3,4 | Junhao Zheng1,2,3,4 | Yali Wang1,2,3,4 | Meijie Chen5 | Yangyang Xie1,2,3,4 | Hongjun Chen1,2,3,4 | Jingwei Cai1,2,3,4 | Haoyu Pan1,2,3,4 | Shihao Li1,2,3,4 | Renan Jin1,2,3,4 | Junjie Xu1,2,3,4 | Xiao Liang1,2,3,4,5 \u003Cbr>1Key Laboratory of Laparoscopic Technology of Zhejiang Province, Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China | 2Zhejiang Minimal Invasive Diagnosis and Treatment Technology Research Center of Severe Hepatobiliary Disease, Zhejiang Research and Development Engineering Laboratory of Minimally Invasive Technology and Equipment, Hangzhou, China | 3Zhejiang University Cancer Center, Hangzhou, China | 4Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China | 5Hangzhou Medical College, Hangzhou, China\u003Cbr>Correspondence: Junjie Xu ([walter235@zju.edu.cn](walter235@zju.edu.cn)) | Xiao Liang ([srrshlx@zju.edu.cn](srrshlx@zju.edu.cn))\u003Cbr>Received: 14 November 2024 | Revised: 23 April 2025 | Accepted: 23 November 2025\u003Cbr>Keywords: HCC | lncRNAs | MPT-driven necrosis | organoid | prognostic signature |\n| --- |\n| ABSTRACT\u003Cbr>Background: Mitochondrial permeability transition (MPT)-driven necrosis, a recently identified form of programmed cell death, significantly influences tumor progression, therapy response, and prognosis. However, research on mitochondrial permeability transition-driven necrosis-related long non-coding ribonucleic acids (MPTDNRlncRNAs) in hepatocellular carcinoma (HCC) remains limited.\u003Cbr>Methods: In the current study, we aimed to construct an MPTDNRlncRNA signature to predict survival and classify patients with HCC. RNA sequencing and clinical data were sourced from the Cancer Genome Atlas database, while MPT-driven necrosislinked genes were obtained from the Gene Set Enrichment Analysis database. We identified MPTDNRlncRNAs in HCC tumor tissues and deployed the least absolute shrinkage and selection operator-Cox analysis to construct a predictive lncRNA signature. Immune cell infiltration variations were analyzed between high-and low-risk subgroups. The MPTDNRlncRNA signature performance was estimated using statistical methodologies, and bioinformatics methods were utilized to investigate functional and pathway differences across risk groups.\u003Cbr>Results: A seven-lncRNA signature specific to HCC was developed, and its predictive accuracy was systematically evaluated using survival analysis, time-dependent receiver operating characteristic curves, and Cox regression analyses. Correlation analysis demonstrated a strong association between the lncRNA signature and immune cell infiltration, several immune checkpoint targets, and its significant prognostic value for patients with HCC. Additionally, LINC02313 was recognized as a hub lncRNA in vitro, demonstrating its role in promoting cell proliferation and tumor metastasis. Finally, we validated the function of LINC02313 using a liver cancer organoid model.\u003Cbr>Conclusion: The effective construction of an MPT-driven necrosis-related prognostic model highlights its potential to independently predict the prognosis of patients with HCC. These findings not only deepen our understanding of MPT-driven |\n|  |\n| Yang Liu, Liye Tao, and Zefeng Shen are equally contributed to this study. |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2025 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. |\n\nCancer Medicine, 2026; 15:e71445 1 of 21  \n[https://doi.org/10.1002/cam4.71445](https://doi.org/10.1002/cam4.71445)  \nnecrosis but also offer novel theoretical foundatio","cbCaip1mBiMNZZyh","https://ap.wps.com/l/cbCaip1mBiMNZZyh","pdf",6194066,21,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion","[{\"question\":\"What is the study’s main goal for hepatocellular carcinoma patients?\",\"answer\":\"To develop an MPT-driven necrosis-related lncRNA signature that predicts survival and classifies HCC patients into risk groups, with prognostic performance assessed statistically.\"},{\"question\":\"How were candidate lncRNAs and the predictive signature constructed?\",\"answer\":\"RNA sequencing and clinical data were obtained from TCGA, MPT-driven necrosis-linked genes were taken from GSEA, and a seven-lncRNA signature was built using LASSO-Cox analysis on HCC tumor tissues.\"},{\"question\":\"What evidence links the signature to immune features and HCC prognosis?\",\"answer\":\"Correlation analyses associate the lncRNA signature with immune cell infiltration and immune checkpoint targets, and survival-focused analyses demonstrate significant prognostic value between high- and low-risk groups.\"},{\"question\":\"How was the role of LINC02313 validated experimentally?\",\"answer\":\"LINC02313 was identified as a hub lncRNA and its function was further validated using a liver cancer organoid model to support its role in promoting proliferation and metastasis.\"}]","A Novel MPT-Driven Necrosis-Related lncRNA Signature for Prognostic Prediction in Hepatocellular Carcinoma - Validation Using Organoids | PDF",1790084977,53,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09c9f2a2c2b54a4f6c6a7a2eb549c935.webp",983,1291,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f1ed44d3f6cae0bf0191e95ee53e143.webp",982,1290,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/06dff118220518a9ed881c0843ca3253.webp",981,1289,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb7df67dbdc8d1ef722f3ffd70d0114f.webp",980,1287]